Ataraxis
Ataraxis is an AI-based diagnostic platform that helps doctors develop personalized treatment plans [1]. The company was founded in 2023 as a spinout from New York University [1][3], with principal investigators Jan Witowski MD PhD and Krzysztof J. Geras PhD [1]. In March 2025, Ataraxis AI announced a $20.4 million Series A funding round led by AIX Ventures, with participation from Floating Point, Thiel Bio, Founders Fund, Bertelsmann Investments, Giant Ventures and Obvious Ventures [2]. The company is based in New York City [5]. Ataraxis Breast, described as an AI-native prognostic and predictive platform for breast cancer, was clinically validated to be 30 percent more accurate than the current standard of care [4].
Funding history
- Ataraxis AI announced a $20.4 million Series A on March 5, 2025, led by AIX Ventures with participation from Floating Point, Thiel Bio, Founders Fund, Bertelsmann Investments, Giant Ventures and Obvious Ventures.[2]
Product
- Ataraxis Breast, described as the world's first AI-native prognostic/predictive platform for breast cancer, was clinically validated in a landmark study to be 30 percent more accurate than the current standard of care.[4]
Founded
- Ataraxis spun out of New York University in 2023 and raised a seed round that year, founded by Jan Witowski and Krzysztof Geras.[3]
Deals & lineage
Spun out of
New York University
NYU, whose Technology Opportunities and Ventures office lists AI startups formed on NYU innovations, including Clarifai (2013, PI Matthew Zeiler)
Something wrong or missing? Send a correction. Fixed within 24 hours.